{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:34:44Z","timestamp":1787952884027,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess the accuracy of conventional MRI with T1- and T2-weighted sequences in detecting lymphatic nodal spread (N1) in intermediate- and high-risk prostate cancer (PCa) patients via morphological criteria alone, extended pelvic lymph node dissection (ePLND) was used as the reference standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational study included patients between 2009 and 2016 with intermediate- and high-risk PCa according to the D\u2019Amico criteria and an estimated risk of N1\u2009&gt;\u200920% on the basis of the Briganti nomogram. All patients underwent MRI prior to ePLND. Interobserver analysis was conducted across three centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-nine men, mean age 67 (5.7 SD), 93% high-risk PCa patients and 39.4% with N1 disease, according to ePLND, were evaluated. The pooled sensitivity of MRI for detecting N1 was 24.6% (95% CI: 16.3\u201335.1), whereas the pooled specificity was 95% (95% CI: 85.3\u201398.8). Interobserver agreement was moderate (Fleiss\u2019 \u03ba\u2009=\u20090.56). All readers failed to identify patients with high-volume N1, and the identification of those with a high number of N1 events was inconsistent across readers. The strengths of this study include the high number of N1 cases, with a median of 17 (6\u201340) harvested lymph nodes per participant. Limitations include the time interval between MRI and ePLND (median of 44 days) and the lack of standardized lymph node evaluation criteria, reflecting real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MRI using only T1W and T2W sequences has demonstrated limited effectiveness in lymph node staging for intermediate- and high-risk prostate cancer, even in high-volume metastatic disease. Additionally, interobserver analysis shows only moderate agreement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00261-025-05073-w","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:13:16Z","timestamp":1750979596000},"page":"206-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic performance of conventional MRI using T1W and T2W for primary lymph node staging in intermediate- and high-risk prostate cancer patients prior to pelvic lymph node dissection"],"prefix":"10.1007","volume":"51","author":[{"given":"Georgios","family":"Daouacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Voulgarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Dahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Sundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauritz","family":"Wald\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"1","key":"5073_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1590\/S1677-5538.IBJU.2016.0656","volume":"44","author":"R Tourinho-Barbosa","year":"2018","unstructured":"Tourinho-Barbosa, R., et al., Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol, 2018. 44(1): p. 14-21. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2016.0656","journal-title":"Int Braz J Urol"},{"key":"5073_CR2","doi-asserted-by":"publisher","unstructured":"Cornford, P., et al., EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol, 2024. 86(2): p. 148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","DOI":"10.1016\/j.eururo.2024.03.027"},{"issue":"1","key":"5073_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","volume":"72","author":"N Fossati","year":"2017","unstructured":"Fossati, N., et al., The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol, 2017. 72(1): p. 84-109. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.003","journal-title":"Eur Urol"},{"key":"5073_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.euros.2022.06.014","volume":"44","author":"P Sooriakumaran","year":"2022","unstructured":"Sooriakumaran, P., T.A. Narain, and R. Davda, Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended? Of Course Not! Eur Urol Open Sci, 2022. 44: p. 18-19. https:\/\/doi.org\/10.1016\/j.euros.2022.06.014","journal-title":"Eur Urol Open Sci"},{"issue":"4","key":"5073_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM Hovels","year":"2008","unstructured":"Hovels, A.M., et al., The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol, 2008. 63(4): p. 387-95. https:\/\/doi.org\/10.1016\/j.crad.2007.05.022","journal-title":"Clin Radiol"},{"key":"5073_CR6","doi-asserted-by":"publisher","unstructured":"Caglic, I. and T. Barrett, Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer. Transl Androl Urol, 2018. 7(5): p. 814\u2013823. https:\/\/doi.org\/10.21037\/tau.2018.08.04","DOI":"10.21037\/tau.2018.08.04"},{"issue":"1","key":"5073_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/RLI.0b013e3181bbdc2f","volume":"45","author":"M Eiber","year":"2010","unstructured":"7.Eiber, M., et al., Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol, 2010. 45(1): p. 15-23. https:\/\/doi.org\/10.1097\/RLI.0b013e3181bbdc2f","journal-title":"Invest Radiol"},{"key":"5073_CR8","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.180124","author":"H Wu","year":"2019","unstructured":"Wu, H., et al., Diagnostic Performance of (6)(8)Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis. World J Mens Health, 2019. https:\/\/doi.org\/10.5534\/wjmh.180124","journal-title":"World J Mens Health"},{"key":"5073_CR9","doi-asserted-by":"publisher","unstructured":"Gallach, M., et al., Addressing Global Inequities in Positron Emission Tomography-Computed Tomography (PET-CT) for Cancer Management: A Statistical Model to Guide Strategic Planning. Med Sci Monit, 2020. 26: p. e926544. https:\/\/doi.org\/10.12659\/MSM.926544","DOI":"10.12659\/MSM.926544"},{"key":"5073_CR10","doi-asserted-by":"publisher","unstructured":"Scott, R., et al., PI-RADS v2.1: What has changed and how to report. SA J Radiol, 2021. 25(1): p. 2062. https:\/\/doi.org\/10.4102\/sajr.v25i1.2062","DOI":"10.4102\/sajr.v25i1.2062"},{"issue":"1","key":"5073_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2007.07.035","volume":"53","author":"A Mattei","year":"2008","unstructured":"Mattei, A., et al., The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol, 2008. 53(1): p. 118-25. https:\/\/doi.org\/10.1016\/j.eururo.2007.07.035","journal-title":"Eur Urol"},{"issue":"8","key":"5073_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe, R.G., Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med, 1998. 17(8): p. 857-72.","journal-title":"Stat Med"},{"issue":"2","key":"5073_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1214\/ss\/1009213286","volume":"16","author":"LD Brown","year":"2001","unstructured":"Brown, L.D., T.T. Cai, and A. DasGupts, Interval Estimation for a Binomial Proportion. Statistical Science 2001. 16(2): p. 101-117.","journal-title":"Statistical Science"},{"issue":"1","key":"5073_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12874-019-0724-x","volume":"19","author":"SC Freeman","year":"2019","unstructured":"Freeman, S.C., et al., Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies: MetaDTA. BMC Med Res Methodol, 2019. 19(1): p. 81. https:\/\/doi.org\/10.1186\/s12874-019-0724-x","journal-title":"BMC Med Res Methodol"},{"key":"5073_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.euros.2022.05.007","volume":"41","author":"C Stenman","year":"2022","unstructured":"Stenman, C., et al., Rates of Positive Abdominal Computed Tomography and Bone Scan Findings Among Men with Cambridge Prognostic Group 4 or 5 prostate cancer: A Nationwide Registry Study. Eur Urol Open Sci, 2022. 41: p. 123-125. https:\/\/doi.org\/10.1016\/j.euros.2022.05.007","journal-title":"Eur Urol Open Sci"},{"issue":"9","key":"5073_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1470-2045(08)70203-1","volume":"9","author":"RA Heesakkers","year":"2008","unstructured":"Heesakkers, R.A., et al., MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol, 2008. 9(9): p. 850-6. https:\/\/doi.org\/10.1016\/S1470-2045(08)70203-1","journal-title":"Lancet Oncol"},{"issue":"4","key":"5073_CR17","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.crad.2015.12.001","volume":"71","author":"C von Below","year":"2016","unstructured":"von Below, C., et al., Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer. Clin Radiol, 2016. 71(4): p. 328-34. https:\/\/doi.org\/10.1016\/j.crad.2015.12.001","journal-title":"Clin Radiol"},{"key":"5073_CR18","doi-asserted-by":"publisher","unstructured":"Vallini, V., et al., Staging of pelvic lymph nodes in patients with prostate cancer: Usefulness of multiple b value SE-EPI diffusion-weighted imaging on a 3.0 T MR system. Eur J Radiol Open, 2016. 3: p. 16\u201321. https:\/\/doi.org\/10.1016\/j.ejro.2015.11.004","DOI":"10.1016\/j.ejro.2015.11.004"},{"key":"5073_CR19","doi-asserted-by":"publisher","unstructured":"Lebastchi, A.H., et al., Comparison of cross-sectional imaging techniques for the detection of prostate cancer lymph node metastasis: a critical review. Transl Androl Urol, 2020. 9(3): p. 1415\u20131427. https:\/\/doi.org\/10.21037\/tau.2020.03.20","DOI":"10.21037\/tau.2020.03.20"},{"issue":"10231","key":"5073_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M.S., et al., Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet, 2020. 395(10231): p. 1208-1216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"issue":"4","key":"5073_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera, M., et al., Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol, 2020. 77(4): p. 403-417. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049","journal-title":"Eur Urol"},{"issue":"1","key":"5073_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13550-022-00918-7","volume":"12","author":"J Ingvar","year":"2022","unstructured":"Ingvar, J., et al., Assessing the accuracy of [(18)F]PSMA-1007 PET\/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res, 2022. 12(1): p. 48. https:\/\/doi.org\/10.1186\/s13550-022-00918-7","journal-title":"EJNMMI Res"},{"issue":"3","key":"5073_CR23","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1016\/j.eururo.2020.06.022","volume":"78","author":"P Cornford","year":"2020","unstructured":"Cornford, P., et al., Prostate-specific Membrane Antigen Positron Emission Tomography Scans Before Curative Treatment: Ready for Prime Time? Eur Urol, 2020. 78(3): p. e125-e128. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.022","journal-title":"Eur Urol"},{"issue":"3","key":"5073_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.juro.2015.03.025","volume":"194","author":"A de Gorski","year":"2015","unstructured":"de Gorski, A., et al., Accuracy of Magnetic Resonance Imaging\/Ultrasound Fusion Targeted Biopsies to Diagnose Clinically Significant Prostate Cancer in Enlarged Compared to Smaller Prostates. J Urol, 2015. 194(3): p. 669-73. https:\/\/doi.org\/10.1016\/j.juro.2015.03.025","journal-title":"J Urol"},{"issue":"4","key":"5073_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","volume":"313","author":"MM Siddiqui","year":"2015","unstructured":"Siddiqui, M.M., et al., Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA, 2015. 313(4): p. 390-7. https:\/\/doi.org\/10.1001\/jama.2014.17942","journal-title":"JAMA"},{"key":"5073_CR26","doi-asserted-by":"publisher","unstructured":"Schumacher, M.C., et al., [C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. Scand J Urol, 2014: p. 1\u20138. Available from: https:\/\/doi.org\/^https:\/\/doi.org\/10.3109\/21681805.2014.932840","DOI":"10.3109\/21681805.2014.932840"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-025-05073-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-025-05073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:03:50Z","timestamp":1769148230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-025-05073-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["5073"],"URL":"https:\/\/doi.org\/10.1007\/s00261-025-05073-w","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}